PubMed ID:
18955056
Public Release Type:
Journal
Publication Year: 2008
Affiliation: Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA. nchalasa@iupui.edu
DOI:
https://doi.org/10.1053/j.gastro.2008.09.011
Authors:
Hoofnagle J,
Bonkovsky H,
Fontana RJ,
Fontana RJ,
Serrano J,
Serrano J,
Watkins PB,
Bonkovsky HL,
Vuppalanchi R,
Chalasani N,
Chalasani N,
Appleton P,
Avigan M,
Beaver K,
Bonacini M,
Conjeevaram H,
Corne A,
Davern T,
Davern T,
Drug Induced Liver Injury Network (DILIN),
Freston J,
Gordon S,
Guess H,
Hayashi P,
Kridler J,
Levine RA,
Lewis J,
Lumeng L,
Maggio M,
Maliakkal B,
McHutchison J,
Molleston J,
Partovi K,
Plummer A,
Protiva P,
Pusek S,
Rochon J,
Rochon J,
Rockey D,
Rosson R,
Russo M,
Seeff L,
Senior J,
Smialek M,
Smith A,
Watkins P,
Welch S,
Worley J,
Yang H,
Yang H
Idiosyncratic drug-induced liver injury (DILI) is among the most common causes of acute liver failure in the United States, accounting for approximately 13% of cases. A prospective study was begun in 2003 to recruit patients with suspected DILI and create a repository of biological samples for analysis. This report summarizes the causes, clinical features, and outcomes from the first 300 patients enrolled.